SRH Wald-Klinikum Gera

Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) (2017) Untch M, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, et al. Conference contribution Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibition (2017) Heppt M, Heinzerling L, Kaehler K, Forschner A, Kirchberger M, Loquai C, Meissner M, et al. Conference contribution Interleukin-2 and Checkpoint Inhibition as a successful Therapy Sequence for metastatic Melanoma: Case Report and retrospective Analysis in 52 Patients (2017) Cosgarea , Zimmer L, Weide B, Gutzmer R, Heinzerling L, Weishaupt C, Pfoehler C, et al. Conference contribution Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition (2017) Heppt MV, Heinzerling L, Kaehler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, et al. Journal article Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years (2017) Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ, Fine SW, et al. Journal article LOGIST - A local observational GIST registry: A non-interventional registry to observe patients with gastrointestinal stromal tumors (GIST) after R0/R1 resection - with or without adjuvant therapy with imatinib (CSTI571BDE77) - an interim analysis with 5 (2016) Reichardt P, Quietzsch D, Stuebs P, Cameron S, Gellert K, Wilhelm M, Killing B, et al. Conference contribution Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial) (2016) Hecht M, Hahn D, Beutner D, Reichert D, Goehler T, Wurm R, Welslau M, et al. Conference contribution Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial) (2016) Hecht M, Hahn D, Beutner D, Reichert D, Goehler T, Wurm R, Welslau M, et al. Conference contribution Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer (2016) Heppner BI, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmidt W, Eidtmann H, et al. Conference contribution Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29) (2016) Von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, Hilfrich J, et al. Journal article